Published in Proc Natl Acad Sci U S A on November 11, 1997
P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol (2000) 5.64
Identification of multiple cyclin subunits of human P-TEFb. Genes Dev (1998) 4.73
The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev (1998) 4.38
Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J (1998) 3.05
MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner. Mol Cell Biol (2003) 2.90
The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat. J Virol (1998) 2.51
Cellular gene expression upon human immunodeficiency virus type 1 infection of CD4(+)-T-cell lines. J Virol (2003) 2.46
CDK-9/cyclin T (P-TEFb) is required in two postinitiation pathways for transcription in the C. elegans embryo. Genes Dev (2002) 2.36
PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo. J Virol (1998) 1.99
Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines. J Virol (1998) 1.93
CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA. Mol Cell Biol (2000) 1.89
Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T. Proc Natl Acad Sci U S A (1999) 1.87
Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. Proc Natl Acad Sci U S A (1999) 1.82
RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication. J Virol (2002) 1.80
Activation of human immunodeficiency virus transcription in T cells revisited: NF-kappaB p65 stimulates transcriptional elongation. J Virol (2001) 1.61
Relief of two built-In autoinhibitory mechanisms in P-TEFb is required for assembly of a multicomponent transcription elongation complex at the human immunodeficiency virus type 1 promoter. Mol Cell Biol (2000) 1.54
A 1.3-A resolution crystal structure of the HIV-1 trans-activation response region RNA stem reveals a metal ion-dependent bulge conformation. Proc Natl Acad Sci U S A (1998) 1.50
Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines. J Virol (2001) 1.48
Transcriptional regulation of HIV-1 gene expression by p53. Cell Cycle (2010) 1.47
Interaction between cyclin T1 and SCF(SKP2) targets CDK9 for ubiquitination and degradation by the proteasome. Mol Cell Biol (2001) 1.40
A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A (2002) 1.39
Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. J Virol (1999) 1.38
A cofactor, TIP30, specifically enhances HIV-1 Tat-activated transcription. Proc Natl Acad Sci U S A (1998) 1.37
Coordination of transcription factor phosphorylation and histone methylation by the P-TEFb kinase during human immunodeficiency virus type 1 transcription. J Virol (2004) 1.30
Transient induction of cyclin T1 during human macrophage differentiation regulates human immunodeficiency virus type 1 Tat transactivation function. J Virol (2002) 1.29
Differential acetylation of Tat coordinates its interaction with the co-activators cyclin T1 and PCAF. EMBO J (2002) 1.27
Targeting of CDK8 to a promoter-proximal RNA element demonstrates catalysis-dependent activation of gene expression. Nucleic Acids Res (1998) 1.26
Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). J Virol (2004) 1.26
Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology (2006) 1.25
Effects of prostratin on Cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cells. Retrovirology (2006) 1.17
Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology (2009) 1.17
The STAT3 NH2-terminal domain stabilizes enhanceosome assembly by interacting with the p300 bromodomain. J Biol Chem (2008) 1.17
Acetylation of conserved lysines in the catalytic core of cyclin-dependent kinase 9 inhibits kinase activity and regulates transcription. Mol Cell Biol (2008) 1.15
Antiapoptotic function of Cdk9 (TAK/P-TEFb) in U937 promonocytic cells. J Virol (2001) 1.14
Dephosphorylation of CDK9 by protein phosphatase 2A and protein phosphatase-1 in Tat-activated HIV-1 transcription. Retrovirology (2005) 1.13
Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology (2007) 1.11
R region sequences in the long terminal repeat of a murine retrovirus specifically increase expression of unspliced RNAs. J Virol (1999) 1.10
Transcriptional cofactor CA150 regulates RNA polymerase II elongation in a TATA-box-dependent manner. Mol Cell Biol (1999) 1.08
Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism. Mol Cell Biol (1999) 1.07
Functional differences between human and bovine immunodeficiency virus Tat transcription factors. J Virol (2000) 1.07
Protein phosphatase-1 activates CDK9 by dephosphorylating Ser175. PLoS One (2011) 1.06
A second-site mutation that restores replication of a Tat-defective human immunodeficiency virus. J Virol (1999) 1.06
HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription. Biochem J (2002) 1.05
The secondary structure of the R region of a murine leukemia virus is important for stimulation of long terminal repeat-driven gene expression. J Virol (1998) 1.04
Human and rodent transcription elongation factor P-TEFb: interactions with human immunodeficiency virus type 1 tat and carboxy-terminal domain substrate. J Virol (1999) 1.03
Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins. J Virol (2005) 1.03
Expression of a protein phosphatase 1 inhibitor, cdNIPP1, increases CDK9 threonine 186 phosphorylation and inhibits HIV-1 transcription. J Biol Chem (2010) 1.02
Stimulation of Tat-associated kinase-independent transcriptional elongation from the human immunodeficiency virus type-1 long terminal repeat by a cellular enhancer. EMBO J (1999) 0.99
The human I-mfa domain-containing protein, HIC, interacts with cyclin T1 and modulates P-TEFb-dependent transcription. Mol Cell Biol (2003) 0.98
HIV-1 replication and latency are regulated by translational control of cyclin T1. J Mol Biol (2011) 0.97
Lost in transcription: molecular mechanisms that control HIV latency. Viruses (2013) 0.96
Inhibition of human immunodeficiency virus type-1 by cdk inhibitors. AIDS Res Ther (2010) 0.92
HIV-1 Tat interacts with LIS1 protein. Retrovirology (2005) 0.92
Tat-SF1 is not required for Tat transactivation but does regulate the relative levels of unspliced and spliced HIV-1 RNAs. PLoS One (2009) 0.88
Complex effects of flavopiridol on the expression of primary response genes. Cell Div (2012) 0.88
Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription. Antimicrob Agents Chemother (2004) 0.87
U30 of 7SK RNA forms a specific photo-cross-link with Hexim1 in the context of both a minimal RNA-binding site and a fully reconstituted 7SK/Hexim1/P-TEFb ribonucleoprotein complex. J Mol Biol (2009) 0.86
Cellular mRNA activates transcription elongation by displacing 7SK RNA. PLoS One (2007) 0.85
Molecular mechanisms of HIV latency. J Clin Invest (2016) 0.85
Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy. J Virol (1999) 0.85
Use of ATP analogs to inhibit HIV-1 transcription. Virology (2012) 0.85
1,25-Dihydroxyvitamin D3 upregulates functional CXCR4 human immunodeficiency virus type 1 coreceptors in U937 minus clones: NF-kappaB-independent enhancement of viral replication. J Virol (1998) 0.83
Dynamics of nascent mRNA folding and RNA-protein interactions: an alternative TAR RNA structure is involved in the control of HIV-1 mRNA transcription. Nucleic Acids Res (2006) 0.81
Cyclin-dependent kinase 9 may as a novel target in downregulating the atherosclerosis inflammation (Review). Biomed Rep (2014) 0.80
Making a Short Story Long: Regulation of P-TEFb and HIV-1 Transcriptional Elongation in CD4+ T Lymphocytes and Macrophages. Biology (Basel) (2012) 0.80
Indirubin 3'-monoxime, from a Chinese traditional herbal formula, suppresses viremia in humanized mice infected with multidrug-resistant HIV. AIDS Res Hum Retroviruses (2014) 0.79
Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy. PLoS One (2014) 0.78
Overview of CDK9 as a target in cancer research. Cell Cycle (2016) 0.78
Human GLI-2 is a tat activation response element-independent Tat cofactor. J Virol (2001) 0.77
The HIV-1 Tat Protein Is Monomethylated at Lysine 71 by the Lysine Methyltransferase KMT7. J Biol Chem (2016) 0.76
Chemicals that footprint DNA: hitting HIV-1 in the minor groove. Proc Natl Acad Sci U S A (1998) 0.76
Drosophila melanogaster positive transcriptional elongation factors regulate metabolic and sex-biased expression in adults. BMC Genomics (2017) 0.75
NF45 and NF90 Bind HIV-1 RNA and Modulate HIV Gene Expression. Viruses (2016) 0.75
The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells. J Transl Med (2016) 0.75
Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice. PLoS One (2017) 0.75
Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev (1997) 6.88
Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J Biol Chem (1996) 6.78
Reversible phosphorylation of the C-terminal domain of RNA polymerase II. J Biol Chem (1996) 5.15
A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology (1988) 4.72
Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem (1994) 4.70
The MO15 cell cycle kinase is associated with the TFIIH transcription-DNA repair factor. Cell (1994) 3.86
Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol (1988) 3.45
Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature (1996) 2.92
Direct interaction of human TFIID with the HIV-1 transactivator tat. Nature (1994) 2.87
Phosphorylation of RNA polymerase by the murine homologue of the cell-cycle control protein cdc2. Nature (1989) 2.81
New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol (1995) 2.61
DNA binding provides a signal for phosphorylation of the RNA polymerase II heptapeptide repeats. Genes Dev (1992) 2.56
Tat-SF1: cofactor for stimulation of transcriptional elongation by HIV-1 Tat. Science (1996) 2.42
PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci U S A (1994) 2.29
Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase. Virology (1993) 2.24
Purification of a Tat-associated kinase reveals a TFIIH complex that modulates HIV-1 transcription. EMBO J (1997) 2.20
The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function. J Virol (1996) 2.16
Anergy and apoptosis in CD8+ T cells from HIV-infected persons. J Immunol (1994) 2.00
The CDC2-related kinase PITALRE is the catalytic subunit of active multimeric protein complexes. Biochem J (1996) 1.83
Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II. Proc Natl Acad Sci U S A (1996) 1.68
Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 Tat protein. J Virol (1990) 1.68
Viral transactivators specifically target distinct cellular protein kinases that phosphorylate the RNA polymerase II C-terminal domain. Nucleic Acids Res (1996) 1.41
Viral transactivators E1A and VP16 interact with a large complex that is associated with CTD kinase activity and contains CDK8. Nucleic Acids Res (1996) 1.20
Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res (1995) 1.00
CDC2-related kinase PITALRE phosphorylates pRb exclusively on serine and is widely expressed in human tissues. J Cell Physiol (1997) 0.92
Sensitivity of immune complex-dissociated p24 antigen testing for early detection of human immunodeficiency virus in infants. Clin Diagn Lab Immunol (1995) 0.84
HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell (1989) 6.11
The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev (1998) 4.38
Monoclonal antibodies against rat immunoglobulin kappa chains. Hybridoma (1982) 3.36
Synergy between HIV-1 Tat and adenovirus E1A is principally due to stabilization of transcriptional elongation. Genes Dev (1990) 2.30
Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase. Virology (1993) 2.24
The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function. J Virol (1996) 2.16
Interferon-mediated, double-stranded RNA-dependent protein kinase is inhibited in extracts from vaccinia virus-infected cells. J Virol (1984) 2.13
Effect of stimulus bandwidth on the perception of /s/ in normal- and hearing-impaired children and adults. J Acoust Soc Am (2001) 2.11
Cooperative calcium binding and ATPase activation in sarcoplasmic reticulum vesicles. J Biol Chem (1980) 2.10
Purification and characterization of vaccinia virus growth factor. Cell (1985) 2.06
Vaccinia virus induces cellular mRNA degradation. J Virol (1983) 2.02
PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo. J Virol (1998) 1.99
A sensitive reporter cell line for HIV-1 tat activity, HIV-1 inhibitors, and T cell activation effects. AIDS Res Hum Retroviruses (1994) 1.95
Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines. J Virol (1998) 1.93
Tat-responsive region RNA of human immunodeficiency virus 1 can prevent activation of the double-stranded-RNA-activated protein kinase. Proc Natl Acad Sci U S A (1990) 1.81
Endemic infectious diseases of the Middle East. Rev Infect Dis (1991) 1.77
Flow cytometry analysis of T cells and continuous T-cell lines from autoimmune MRL/l mice. Nature (1981) 1.56
In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol (2000) 1.51
Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines. J Virol (2001) 1.48
Idiopathic CD4+ T lymphocytopenia in a patient with mycosis fungoides. J Am Acad Dermatol (1994) 1.45
Viral transactivators specifically target distinct cellular protein kinases that phosphorylate the RNA polymerase II C-terminal domain. Nucleic Acids Res (1996) 1.41
p53 is required for both radiation-induced differentiation and rescue of V(D)J rearrangement in scid mouse thymocytes. Genes Dev (1996) 1.41
Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther (2000) 1.37
Influenza virus infection induces functional alterations in peripheral blood lymphocytes. J Immunol (1986) 1.35
Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys. Am J Pathol (1993) 1.34
Epstein-Barr virus-associated B-cell proliferations of diverse clonal origins after bone marrow transplantation in a 12-year-old patient with severe combined immunodeficiency. N Engl J Med (1985) 1.32
Excess intrauterine fetal demise associated with maternal human immunodeficiency virus infection. J Infect Dis (1995) 1.30
Response of individual adenovirus promoters to the products of the E1A gene. Oncogene (1987) 1.30
2-5A accumulates to high levels in interferon-treated, vaccinia virus-infected cells in the absence of any inhibition of virus replication. J Virol (1984) 1.29
Coinjection strategy for visual identification of transgenic mice. Transgenic Res (1991) 1.27
In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther (1999) 1.26
Targeting of CDK8 to a promoter-proximal RNA element demonstrates catalysis-dependent activation of gene expression. Nucleic Acids Res (1998) 1.26
Double-stranded RNA-dependent protein kinase and 2-5A system are both activated in interferon-treated, encephalomyocarditis virus-infected HeLa cells. J Virol (1985) 1.24
Disproportionate expansion of a minor T cell subset in patients with lymphadenopathy syndrome and acquired immunodeficiency syndrome. J Infect Dis (1985) 1.21
Viral transactivators E1A and VP16 interact with a large complex that is associated with CTD kinase activity and contains CDK8. Nucleic Acids Res (1996) 1.20
Mutant adenovirus type 9 E4 ORF1 genes define three protein regions required for transformation of CREF cells. J Virol (1997) 1.20
Fusion as a mediator of cytolysis in mixtures of uninfected CD4+ lymphocytes and cells infected by human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 1.17
Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med (1997) 1.17
Antiapoptotic function of Cdk9 (TAK/P-TEFb) in U937 promonocytic cells. J Virol (2001) 1.14
Rapid word-learning in normal-hearing and hearing-impaired children: effects of age, receptive vocabulary, and high-frequency amplification. Ear Hear (2005) 1.13
Serious infections involving the CDC group Ve bacteria Chryseomonas luteola and Flavimonas oryzihabitans. Rev Infect Dis (1991) 1.12
Granuloma cytokines in murine cysticercosis. Infect Immun (1997) 1.10
The relation between stimulus context, speech audibility, and perception for normal-hearing and hearing-impaired children. J Speech Lang Hear Res (2000) 1.10
Effect of hepatocyte proliferation and cellular DNA synthesis on hepatitis B virus replication. Gastroenterology (1996) 1.07
How does trp repressor bind to its operator? J Biol Chem (1991) 1.06
Comparison of CD8(+) T-cell subsets in HIV-infected rapid progressor children versus non--rapid progressor children. J Allergy Clin Immunol (2001) 1.06
Regulation of CD28 costimulation in human CD8+ T cells. J Immunol (1997) 1.06
GalR mutants defective in repressosome formation. Genes Dev (1999) 1.06
Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther (2000) 1.05
Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery. Hum Gene Ther (1998) 1.04
Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol (2000) 1.04
Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer (2001) 1.04
The perception of amplified speech by listeners with hearing loss: acoustic correlates. J Acoust Soc Am (1995) 1.04
Interferon-gamma expression in jejunal biopsies in experimental human cryptosporidiosis correlates with prior sensitization and control of oocyst excretion. J Infect Dis (2000) 1.03
Quantitation of HIV viral burden by PCR in HIV seropositive Navy personnel representing Walter Reed stages 1 to 6. AIDS Res Hum Retroviruses (1992) 1.01
Cocaine intoxication in a breast-fed infant. Pediatrics (1987) 1.01
Transcription regulation by repressosome and by RNA polymerase contact. Cold Spring Harb Symp Quant Biol (1998) 1.01
Measures of hearing aid gain for real speech. Ear Hear (1996) 1.01
Wild-type and mutant HIV-1 and HIV-2 Tat proteins expressed in Escherichia coli as fusions with glutathione S-transferase. J Acquir Immune Defic Syndr (1994) 1.01
Exon2 of HIV-2 Tat contributes to transactivation of the HIV-2 LTR by increasing binding affinity to HIV-2 TAR RNA. Nucleic Acids Res (1994) 1.00
Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models. Cancer Gene Ther (2011) 0.99
Functional significance of the dinucleotide bulge in stem-loop1 and stem-loop2 of HIV-2 TAR RNA. Virology (1994) 0.98
In vivo and in vitro studies of TrpR-DNA interactions. J Mol Biol (1996) 0.98
Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion. Gene Ther (2002) 0.98
Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine (2009) 0.97
Some theoretical considerations concerning the relation between functional gain and insertion gain. J Speech Hear Res (1988) 0.97
Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. Eur Urol (2005) 0.97
The intrauterine probe electrode. Am J Obstet Gynecol (1991) 0.96
Genotyping of bovine kappa-casein loci following DNA sequence amplification. Biotechnology (N Y) (1990) 0.96
Instability of adenoviral vectors during transport and its implication for clinical studies. Nat Med (1999) 0.96
Isolation of yeast mutants defective for localization of vacuolar vital dyes. Proc Natl Acad Sci U S A (1998) 0.95
Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther (2001) 0.95
SB-202742, a novel beta-lactamase inhibitor isolated from Spondias mombin. J Nat Prod (1994) 0.94
Complex and pure-tone signals in the evaluation of hearing-aid characteristics. J Speech Hear Res (1990) 0.94
Human immunodeficiency virus (HIV) transcripts identified in HIV-related psoriasis and Kaposi's sarcoma lesions. J Clin Invest (1991) 0.92
Hepatocyte gene therapy in a large animal: a neonatal bovine model of citrullinemia. Proc Natl Acad Sci U S A (1999) 0.92
Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther (2001) 0.91
Growth of masking as a measure of response growth in hearing-impaired listeners. J Acoust Soc Am (1987) 0.91
Proliferative signals for suppressor T cells. Helper cells stimulated with pokeweed mitogen in vitro produce a suppressor cell growth factor. J Clin Invest (1986) 0.91
Placental release of distinct DNA-associated micro-particles into maternal circulation: reflective of gestation time and preeclampsia. Placenta (2009) 0.90
Construction and characterization of a potent HIV-2 Tat transdominant mutant protein. J Acquir Immune Defic Syndr (1994) 0.90
Thymic nurse cells are sites of thymocyte apoptosis. J Immunol (1994) 0.89
Ca(2+)-dependent and thapsigargin-inhibited phosphorylation of Na+,K(+)-ATPase catalytic domain following chimeric recombination with Ca(2+)-ATPase. J Biol Chem (1993) 0.89
Interferon-gamma alters expression of endothelial cell-surface glycosphingolipids. Arch Biochem Biophys (1990) 0.89
Suicide gene therapy for treatment of retinoblastoma in a murine model. Hum Gene Ther (1999) 0.89
Expression of IL-15 and IL-4 in IFN-gamma-independent control of experimental human Cryptosporidium parvum infection. Cytokine (2001) 0.88
Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression. Cancer Gene Ther (2001) 0.88